Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 11.7% from a year ago
Net receivables stood at $31.14M at the end of Q2 FY2026, up 11.7% from a year earlier and down 6.8% from the prior quarter. Over 3 fiscal years it compounded at -44.2% a year.
Context
- Net receivables amounted to 5.2% of total assets at the end of Q2 FY2026, up 2.0 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +11.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 25.5M USD
- Year-over-year change
- -33.8%
- 4-year CAGR
- -31.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.5M | -33.8% |
| FY2024 | 2024-12-31 | 38.52M | -30.9% |
| FY2023 | 2023-12-31 | 55.72M | -62.0% |
| FY2022 | 2022-12-31 | 146.81M | +24.9% |
| FY2021 | 2021-12-31 | 117.51M | — |
Net Receivables vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's Jun 2026 net receivables of $31.14M is the 6th highest of the 9 companies compared; the peer median is $139.81M.
- Its year-over-year change of +11.7% is the 3rd highest of 9, against a peer median of -3.8%.
- Net receivables amounts to 5.2% of total assets for MRVI, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $441.8M | -6.0% | -1.5% | 4.3% | |
| Sep 2026 | $209.8M | +14.1% | +0.3% | 8.0% | |
| Jun 2026 | $157.71M | +0.5% | +10.9% | 5.3% | |
| Sep 2026 | $143.42M | -24.2% | -0.5% | 8.4% | |
| Aug 2026 | $136.2M | -1.6% | -1.4% | 4.1% | |
| Jun 2026 | $31.14M | +11.7% | -44.2% | 5.2% | |
| Mar 2026 | $29.35M | -7.3% | +23.6% | 3.8% | |
| Mar 2026 | $16.64M | -53.1% | -8.1% | 2.6% | |
| Mar 2026 | $13.06M | +42.4% | -38.3% | 3.3% | |
| Peer median (excluding MRVI) | $139.81M | -3.8% | -1.0% | 4.2% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 551.27M | 632.14M | 574.96M | 322.4M | 216.89M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 117.51M | 146.81M | 55.72M | 38.52M | 25.5M |
| Inventory | 51.56M | 43.15M | 51.4M | 50.08M | 40.5M |
| Other Current Assets | 0 | 25.8M | 17.83M | 18.15M | 13.37M |
| Total Current Assets | 740.04M | 847.9M | 699.91M | 429.15M | 296.25M |
| Property, Plant & Equipment (Net) | 95.43M | 116.59M | 222.65M | 217.03M | 1.22M |
| Goodwill | 152.77M | 283.67M | 326.03M | 159.88M | 129.43M |
| Intangible Assets | 117.57M | 216.66M | 220.99M | 194.96M | 151.54M |
| Long-term Investments | 0 | 11.36M | 8.56M | 0 | 0 |
| Tax Assets | 808.12M | 765.8M | 0 | 0 | 0 |
| Other Non-current Assets | 4.36M | 40.33M | 9.32M | 7.24M | 192.14M |
| Total Non-current Assets | 1.18B | 1.43B | 787.54M | 579.1M | 474.33M |
| Total Assets | 1.92B | 2.28B | 1.49B | 1.01B | 770.58M |
| Account Payables | 8.15M | 5.99M | 10.73M | 11.96M | 0 |
| Short-term Debt | 6M | 5.44M | 5.44M | 5.44M | 5.44M |
| Tax Payables | 1.4M | 1.03M | 1M | 779K | 24.49M |
| Deferred Revenue | 12.64M | 3.09M | 3.36M | 3.29M | 0 |
| Other Current Liabilities | 18.89M | 69.48M | 47.62M | 18.71M | 39.48M |
| Total Current Liabilities | 93.78M | 110.14M | 87.47M | 56.97M | 44.92M |
| Long-term Debt | 524.59M | 522M | 518.71M | 290.49M | 30.14M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 713.64M | 693.38M | 11.98M | 11.09M | 322.81M |
| Total Non-current Liabilities | 1.28B | 1.27B | 610.1M | 374.06M | 352.95M |
| Total Liabilities | 1.37B | 1.38B | 697.57M | 431.04M | 397.87M |
| Common Stock | 2.55M | 2.55M | 2.51M | 2.53M | 2.56M |
| Retained Earnings | 184.56M | 404.77M | 285.74M | 140.89M | 10.12M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 524K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 229.86M | 360.03M | 373.13M | 251.92M | 160.33M |
| Total Equity | 545.36M | 905.24M | 789.88M | 577.21M | 372.71M |
| Total Debt | 575.22M | 585.26M | 610.97M | 376.69M | 35.58M |
| Net Debt | 23.95M | (46.88M) | 36.01M | 54.29M | (181.31M) |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.